Plant Name: Trichosanthes bracteata
Taxonomic Information:
Plant ID: NPO13679
Plant Latin Name: Trichosanthes bracteata
Taxonomy Genus: Trichosanthes
Taxonomy Family: Cucurbitaceae
Plant External Links:
NCBI TaxonomyDB:
486425
Plant-of-the-World-Online:
294157-1
Used in Medicines:
Country/Region:
South Korea; IndiaTraditional Medicine System:
Indian Folk; Unani; Ayurveda; SiddhaGeographical Distribution:
Bangladesh; Myanmar; Nepal; India; China; Sri Lanka; South Korea
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADORA3; ADORA1; ADORA2A; | |
| TSHR; | |
| ADK; | |
| STAT6; | |
| SLC28A2; SLC28A1; SLC28A3; | |
| ABCC1; | |
| ITGAL; HTT; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| SLC superfamily of solute carriers | SLC28A2 | Sodium/nucleoside cotransporter 2 | O43868 | CHEMBL5780 |
| SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
| SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Unclassified | ITGAL | Leukocyte adhesion glycoprotein LFA-1 alpha | P20701 | CHEMBL1803 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 1.977E-08 | 8.612E-05 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 4.741E-08 | 1.475E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 6.769E-08 | 1.842E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0051179; localization | GO:0015860; purine nucleoside transmembrane transport | 7.290E-07 | 1.249E-03 | SLC28A2, SLC28A3 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 7.457E-07 | 1.249E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 7.290E-07 | 1.249E-03 | SLC28A1, SLC28A3 |
| MF | GO:0005215; transporter activity | GO:0015211; purine nucleoside transmembrane transporter activity | 7.290E-07 | 1.249E-03 | SLC28A2, SLC28A3 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 9.919E-07 | 1.440E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 9.919E-07 | 1.440E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 2.186E-06 | 1.904E-03 | SLC28A1, SLC28A3 |
| BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 2.186E-06 | 1.904E-03 | SLC28A1, SLC28A3 |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 2.186E-06 | 1.904E-03 | ADORA1, ADORA2A |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 4.370E-06 | 3.398E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 7.853E-06 | 5.897E-03 | CYP1A1, CYP1A2, CYP1B1 |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 1.052E-05 | 7.390E-03 | ABCC1, ADORA1, ADORA2A, ADORA3, SLC28A1, SLC28A2, SLC28A3, TSHR |
| CC | GO:0044456; synapse part | GO:0099055; integral component of postsynaptic membrane | 2.615E-05 | 1.212E-02 | ADORA1, ADORA2A |
| CC | GO:0043226; organelle | GO:0097504; Gemini of coiled bodies | 4.787E-05 | 2.127E-02 | SMN1, SMN2 |
| CC | GO:0032991; macromolecular complex | GO:0032797; SMN complex | 5.654E-05 | 2.414E-02 | SMN1, SMN2 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 4.943E-06 | 2.125E-04 | CYP1A2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.529E-05 | 3.288E-04 | CYP1A2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 3.058E-05 | 4.383E-04 | CYP1A2, CYP1A1, CYP1B1 |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 7.434E-05 | 6.393E-04 | ADORA2A, ADORA3, ADORA1, TSHR |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 4.334E-05 | 4.659E-04 | CYP1A2, CYP1A1, CYP1B1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 1.347E-04 | 9.654E-04 | ABCC1, ADORA3, ADORA1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 5.953E-04 | 3.657E-03 | ADORA2A, ADORA1, TSHR |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 8.133E-04 | 4.371E-03 | CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 1.019E-03 | 4.870E-03 | ADORA1, TSHR |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.371E-03 | 5.894E-03 | CYP1A2, CYP1A1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ADORA3; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ADORA1; ADORA2A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | ADORA1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ADORA1; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADORA1; ADORA2A; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; |
| NA: NA | Hepatitis C virus infection | NA | ADORA3; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA1; ADORA2A; ADORA3; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ADK; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ADORA2A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA1; ADORA2A; |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADORA2A; ADK; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ADORA1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADORA1; ADORA2A; |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK; |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1; |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
